Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Patient Preference 1Neoplasms 1Lymphoma, Non-Hodgkin 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1CD20-positive Hematological Malignancies 1Bile Duct Neoplasms 1Advanced Cancers 1

Interventions

Pemetrexed 1Injections, Subcutaneous 1Infusions, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer × Injections, Subcutaneous × 1 year × Clear all
NCT06505837 2025-08-28

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer(NSCLC)

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Active not recruiting
395 enrolled
Thoracic

Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡